Journey Medical Corporation (NASDAQ:DERM) Q3 2023 Earnings Call Transcript

Andy Fleszar: Excellent. That’s very helpful. And now switching gears, one final question from me on Accutane. It sounds like you are having continued growth in market share at 14.5%. But I know that we had a bit of a slowdown in isotretinoin market overall last year. Have things kind of returned to the expected long-term growth rate there and any additional color you can provide on the overall market?

Claude Maraoui: Sure. Yeah, Andy. Just to give you some market background on the isotretinoin market in 2021 and that’s all isotretino included, there was about 2,075,000 prescriptions, and in 2022, about the same amount, and now in 2023 through the first three quarters, we are at about 1.5% and change. So it looks like it is going to be close to that $2 million prescription market. There was a touch of a slowdown, but I think we are starting to see that ramp back up. So it’s holding very strongly. I think we saw some good single digits year-over-year. That’s just backed off a bit, but it’s very nominal.

Andy Fleszar: Great.

Claude Maraoui: Thank you.

Andy Fleszar: Thanks for additional color and thank you for taking the questions.

Claude Maraoui: Sure. Absolutely.

Operator: This concludes our question-and-answer session, as well as our call for today. Thank you for attending today’s presentation. You may now disconnect.